Skip to main content
SpringerLink
Log in

GER and Antacid Medications

  • Chapter
  • First Online:
Gastroesophageal Reflux in Children

  • 1064 Accesses

Abstract

Gastric acid secretion is a physiological process essential for food digestion. It is regulated by paracrine, hormonal, and neural pathways. Antacids, surface-protective agents, and antisecretory agents are used for treating gastroesophageal reflux disease (GER). Antacids are helpful for immediate symptomatic relief but are not recommended for chronic use. Histamine-2 receptor antagonists have a role in the management of episodic and mild symptoms, particularly for infrequent GER or reflux-related symptoms. Proton pump inhibitors (PPIs) have become some of the most frequently prescribed medications in both children and adults, and their effectiveness for treatment of peptic conditions in the pediatric population has been established. They are well tolerated in both infants and children, but as with any other pharmacologic therapy, PPIs are not exempt of side effects, and risk-benefit should be assessed in individual cases, especially when a chronic use is necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Sakai H, Fujii T, Takeguchi N. Proton-potassium (H(+)/K(+)) ATPases: properties and roles in health and diseases. Met Ions Life Sci. 2016;16:459–83.

    Article  PubMed  CAS  Google Scholar 

  2. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60.

    Article  PubMed  CAS  Google Scholar 

  3. Schubert ML, Makhlouf GM. Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats. Gastroenterology. 1993;104(3):834–9.

    Article  PubMed  CAS  Google Scholar 

  4. Schubert ML, Makhlouf GM. Neural, hormonal, and paracrine regulation of gastrin and acid secretion. Yale J Biol Med. 1992;65(6):553–60. discussion 621-3

    PubMed  PubMed Central  CAS  Google Scholar 

  5. Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49(4):498–547.

    Article  PubMed  Google Scholar 

  6. Tsou VM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics. 1991;87(2):148–51.

    PubMed  CAS  Google Scholar 

  7. Pivnick EK, Kerr NC, Kaufman RA, Jones DP, Chesney RW. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr (Phila). 1995;34(2):73–8.

    Article  CAS  Google Scholar 

  8. Carroll MW, Jacobson K. Gastroesophageal reflux disease in children and adolescents: when and how to treat. Paediatr Drugs. 2012;14(2):79–89.

    Article  PubMed  Google Scholar 

  9. Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev. 2014;11:CD008550.

    Google Scholar 

  10. Corvaglia L, Aceti A, Mariani E, De Giorgi M, Capretti MG, Faldella G. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants. Aliment Pharmacol Ther. 2011;33(4):466–70.

    Article  CAS  PubMed  Google Scholar 

  11. Corvaglia L, Spizzichino M, Zama D, Aceti A, Mariani E, Legnani E, et al. Sodium Alginate (Gaviscon(R)) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants. Early Hum Dev. 2011;87(12):775–8.

    Article  PubMed  CAS  Google Scholar 

  12. Del Buono R, Wenzl TG, Ball G, Keady S, Thomson M. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch Dis Child. 2005;90(5):460–3.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ummarino D, Miele E, Martinelli M, Scarpato E, Crocetto F, Sciorio E, et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. J Pediatr Gastroenterol Nutr. 2015;60(2):230–5.

    Article  PubMed  CAS  Google Scholar 

  14. Reimer C, Lodrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899–909.

    Article  PubMed  CAS  Google Scholar 

  15. Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59–66.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon double action liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531–7.

    PubMed  PubMed Central  Google Scholar 

  17. Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013;11(12):1585–91. quiz e90

    Article  PubMed  CAS  Google Scholar 

  18. Arguelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med. 1989;86(6A):73–6.

    Article  PubMed  CAS  Google Scholar 

  19. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med. 1990;323(24):1672–80.

    Article  PubMed  CAS  Google Scholar 

  20. van der Pol R, Langendam M, Benninga M, van Wijk M, Tabbers M. Efficacy and safety of histamine-2 receptor antagonists. JAMA Pediatr. 2014;168(10):947–54.

    Article  PubMed  Google Scholar 

  21. Hyman PE, Garvey TQ 3rd, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr. 1987;110(5):794–6.

    Article  PubMed  CAS  Google Scholar 

  22. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35(8):976–83.

    Article  PubMed  CAS  Google Scholar 

  23. Dutta U, Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin N Am. 2013;42(1):93–117.

    Article  Google Scholar 

  24. Jones AW. Perspectives in drug development and clinical pharmacology: the discovery of histamine H1 and H2 antagonists. Clin Pharmacol Drug Dev. 2016;5(1):5–12.

    Article  PubMed  CAS  Google Scholar 

  25. Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol. 2015;80(2):200–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):e817–20.

    Article  PubMed  Google Scholar 

  27. Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012;129(1):e40–5.

    Article  PubMed  Google Scholar 

  28. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet. 2005;44(5):441–66.

    Article  PubMed  CAS  Google Scholar 

  29. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997;17(1):22–37.

    PubMed  CAS  Google Scholar 

  30. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013;15(2):119–31.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Furuta K, Adachi K, Aimi M, Shimura S, Mikami H, Nishimura N, et al. Effect of timing of proton pump inhibitor administration on acid suppression. Digestion. 2016;93(2):111–20.

    Article  PubMed  CAS  Google Scholar 

  32. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol. 2007;41(Suppl 2):S226–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Tran A, Rey E, Pons G, Pariente-Khayat A, D’Athis P, Sallerin V, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther. 2002;71(5):359–67.

    Article  PubMed  CAS  Google Scholar 

  34. Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol. 2000;95(11):3101–6.

    Article  PubMed  CAS  Google Scholar 

  35. Lima JJ, Franciosi JP. Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics. 2014;15(11):1405–16.

    Article  PubMed  CAS  Google Scholar 

  36. Lima JJ, Lang JE, Mougey EB, Blake KB, Gong Y, Holbrook JT, et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr. 2013;163(3):686–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003;143(2):219–23.

    Article  PubMed  CAS  Google Scholar 

  38. Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007;44(1):41–4.

    Google Scholar 

  39. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514–20. e4

    Article  PubMed  CAS  Google Scholar 

  40. Davidson G, Wenzl TG, Thomson M, Omari T, Barker P, Lundborg P, et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr. 2013;163(3):692–8. e1-2

    Article  PubMed  CAS  Google Scholar 

  41. Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr. 2012;55(1):14–20.

    CAS  PubMed  Google Scholar 

  42. Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2014;58(2):226–36.

    Article  PubMed  CAS  Google Scholar 

  43. van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127(5):925–35.

    Article  PubMed  Google Scholar 

  44. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185–93.

    Article  PubMed  Google Scholar 

  45. Bjornsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945–54.

    Article  PubMed  CAS  Google Scholar 

  46. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21(2):149–54.

    Article  PubMed  CAS  Google Scholar 

  47. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80–7. 7 e1

    Article  PubMed  CAS  Google Scholar 

  48. Cucchiara S, Minella R, Iervolino C, Franco MT, Campanozzi A, Franceschi M, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child. 1993;69(6):655–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Pfefferkorn MD, Croffie JM, Gupta SK, Molleston JP, Eckert GJ, Corkins MR, et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. J Pediatr Gastroenterol Nutr. 2006;42(2):160–5.

    Article  PubMed  CAS  Google Scholar 

  50. Hassall E, Israel D, Shepherd R, Radke M, Dalvag A, Skold B, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr. 2000;137(6):800–7.

    Article  PubMed  CAS  Google Scholar 

  51. Gunasekaran T, Gupta S, Gremse D, Karol M, Pan WJ, Chiu YL, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr. 2002;35(Suppl 4):S327–35.

    Article  PubMed  CAS  Google Scholar 

  52. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2002;35(Suppl 4):S308–18.

    Article  PubMed  CAS  Google Scholar 

  53. Borrelli O, Rea P, de Bueno MM, et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and lansoprazole for children with gastroesophageal reflux disease. Ital J Pediatr. 2002;28(4):304–9.

    Google Scholar 

  54. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(7):861–7.

    Article  PubMed  CAS  Google Scholar 

  55. Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45(5):520–9.

    Article  CAS  PubMed  Google Scholar 

  56. Tolia V, Youssef NN, Gilger MA, Traxler B, Illueca M. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. J Pediatr Gastroenterol Nutr. 2015;60(Suppl 1):S24–30.

    Article  PubMed  Google Scholar 

  57. Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer GM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;42(4):384–91.

    Article  PubMed  CAS  Google Scholar 

  58. Tsou VM, Baker R, Book L, Hammo AH, Soffer EF, Wang W, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila). 2006;45(8):741–9.

    Article  Google Scholar 

  59. Tolman KG, Taubel J, Warrington S, Chiu YL, Pilmer BL, Pan WJ. Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. Clin Drug Investig. 2006;26(1):21–8.

    Article  PubMed  CAS  Google Scholar 

  60. McLeay SC, Green B, Treem W, Thyssen A, Mannaert E, Kimko H. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years. Clin Pharmacokinet. 2014;53(10):943–57.

    Article  PubMed  CAS  Google Scholar 

  61. Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Sloan S, et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013;57(6):798–807.

    Article  PubMed  CAS  Google Scholar 

  62. Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Silber S, et al. Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. J Pediatr Gastroenterol Nutr. 2014;58(4):510–7.

    Article  PubMed  CAS  Google Scholar 

  63. Skrzydlo-Radomanska B, Radwan P. Dexlansoprazole – a new – generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  64. Kukulka M, Wu J, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2012;54(1):41–7.

    Article  PubMed  CAS  Google Scholar 

  65. Kukulka M, Nudurupati S, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease. Clin Exp Gastroenterol. 2014;7:461–71.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176(2):172–4.

    Article  PubMed  Google Scholar 

  67. Nand B, Bhagat M. Serious and commonly overlooked side effect of prolonged use of PPI. Am J Med. 2014;127(9):e5.

    Article  PubMed  Google Scholar 

  68. Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016;19(9):864–8.

    Article  PubMed  CAS  Google Scholar 

  69. Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706–19.

    Article  PubMed  CAS  Google Scholar 

  70. Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.

    Article  PubMed  Google Scholar 

  71. Hassall E, Shepherd R, Koletzko S, Radke M, Henderson C, Lundborg P. Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study. Aliment Pharmacol Ther. 2012;35(3):368–79.

    Article  PubMed  CAS  Google Scholar 

  72. Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther. 2011;33(7):829–36.

    Article  PubMed  CAS  Google Scholar 

  73. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci. 2008;53(2):385–93.

    Article  PubMed  CAS  Google Scholar 

  74. Freedberg DE, Lamouse-Smith ES, Lightdale JR, Jin Z, Yang YX, Abrams JA. Use of acid suppression medication is associated with risk for C. difficile infection in infants and children: a population-based study. Clin Infect Dis. 2015;61(6):912–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Stark CM, Nylund CM. Side effects and complications of proton pump inhibitors: a pediatric perspective. J Pediatr. 2016;168:16–22.

    Article  PubMed  Google Scholar 

  76. Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56.

    Article  PubMed  CAS  Google Scholar 

  77. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007;150(3):262–7. 7 e1

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children’s Center for Digestive Healthcare, Atlanta, GA, USA

    Jose M. Garza

  2. Neurogastroenterology and Motility, Children’s Healthcare of Atlanta, Atlanta, GA, USA

    Jose M. Garza

  3. Pediatrics, The Ohio State University, Columbus, OH, USA

    Carlo Di Lorenzo

  4. Division of Pediatric Gastroenterology, Nationwide Children’s Hospital, Columbus, OH, USA

    Carlo Di Lorenzo

Authors
  1. Jose M. Garza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlo Di Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Di Lorenzo .

Editor information

Editors and Affiliations

  1. Universitair Ziekenhuis Brussel, Kidz Health Castle, Brussels, Belgium

    Yvan Vandenplas

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Garza, J.M., Di Lorenzo, C. (2017). GER and Antacid Medications. In: Vandenplas, Y. (eds) Gastroesophageal Reflux in Children. Springer, Cham. https://doi.org/10.1007/978-3-319-60678-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-60678-1_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-60677-4

  • Online ISBN: 978-3-319-60678-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation